The San Francisco-based venture capital firm VenBio Partners closed its third life sciences venture capital fund at roughly $394 million, surpassing its original fundraising target.

VenBio Global Strategic Fund III LP mainly targets therapeutics companies developing biopharmaceuticals for unmet medical needs.

The money was raised from existing and new investors